CN101652353A - 用作硬脂酰CoA去饱和酶抑制剂的3-氢喹唑啉-4-酮衍生物 - Google Patents

用作硬脂酰CoA去饱和酶抑制剂的3-氢喹唑啉-4-酮衍生物 Download PDF

Info

Publication number
CN101652353A
CN101652353A CN200880011238A CN200880011238A CN101652353A CN 101652353 A CN101652353 A CN 101652353A CN 200880011238 A CN200880011238 A CN 200880011238A CN 200880011238 A CN200880011238 A CN 200880011238A CN 101652353 A CN101652353 A CN 101652353A
Authority
CN
China
Prior art keywords
oxo
methyl
group
dihydroquinazoline
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200880011238A
Other languages
English (en)
Chinese (zh)
Inventor
德米特里·科尔通
埃里克·帕克希尔
梅拉妮·博塞
杰夫·扎布沃茨基
纳塔利娅·瓦西列维奇
安德烈·格卢什科夫
安德鲁·科尔
叶连娜·梅博罗达
杰弗里·奇泽姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Palo Alto Inc
Original Assignee
CV Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CV Therapeutics Inc filed Critical CV Therapeutics Inc
Publication of CN101652353A publication Critical patent/CN101652353A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN200880011238A 2007-04-11 2008-04-10 用作硬脂酰CoA去饱和酶抑制剂的3-氢喹唑啉-4-酮衍生物 Pending CN101652353A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91122507P 2007-04-11 2007-04-11
US60/911,225 2007-04-11

Publications (1)

Publication Number Publication Date
CN101652353A true CN101652353A (zh) 2010-02-17

Family

ID=39709340

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880011238A Pending CN101652353A (zh) 2007-04-11 2008-04-10 用作硬脂酰CoA去饱和酶抑制剂的3-氢喹唑啉-4-酮衍生物

Country Status (12)

Country Link
US (1) US20080255161A1 (enExample)
EP (1) EP2155695A1 (enExample)
JP (1) JP2010523674A (enExample)
KR (1) KR20100016421A (enExample)
CN (1) CN101652353A (enExample)
AU (1) AU2008239689A1 (enExample)
BR (1) BRPI0809551A2 (enExample)
CA (1) CA2683925A1 (enExample)
IL (1) IL201117A0 (enExample)
MX (1) MX2009010894A (enExample)
RU (1) RU2009141596A (enExample)
WO (1) WO2008127615A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110903253A (zh) * 2019-12-13 2020-03-24 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008043087A2 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
JP2010523653A (ja) * 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体
US20090105283A1 (en) * 2007-04-11 2009-04-23 Dmitry Koltun 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US8609730B2 (en) 2008-01-08 2013-12-17 The Trustees Of The University Of Pennsylvania Rel inhibitors and methods of use thereof
JP2011516498A (ja) * 2008-04-04 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するためのトリアゾロピリジノン誘導体
WO2009124259A1 (en) * 2008-04-04 2009-10-08 Cv Therapeutics, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US20100267752A1 (en) * 2008-10-15 2010-10-21 Gilead Palo Alto, Inc. 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
SG11201406871UA (en) 2012-04-24 2014-11-27 Chugai Pharmaceutical Co Ltd Benzamide derivative
WO2013161853A1 (ja) 2012-04-24 2013-10-31 中外製薬株式会社 キナゾリンジオン誘導体
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
US10239845B2 (en) 2015-02-02 2019-03-26 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
EP3472131B1 (en) 2016-06-17 2020-02-19 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
MA46589A (fr) 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
KR20190108118A (ko) 2017-01-06 2019-09-23 유마니티 테라퓨틱스, 인크. 신경계 장애의 치료를 위한 방법
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
AU2019200683B2 (en) * 2018-02-01 2024-05-30 The University Of Sydney Anti-cancer compounds
MX2020009942A (es) 2018-03-23 2021-01-08 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
KR20220007845A (ko) 2019-01-24 2022-01-19 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
KR20220061945A (ko) * 2019-07-02 2022-05-13 이펙터 테라퓨틱스, 인크. Eif4e-억제 4-옥소-3,4-디히드로피리도[3,4-d]피리미딘 화합물
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
IN202011027502A (enExample) * 2020-06-29 2021-12-31 Council Scient Ind Res
TW202220964A (zh) * 2020-07-24 2022-06-01 美商伊尼製藥股份有限公司 喹唑啉酮hsd17b13抑制劑及其用途
AU2021377248A1 (en) * 2020-11-13 2023-06-22 Inipharm, Inc. Dichlorophenol hsd17b13 inhibitors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
JPS5920668B2 (ja) * 1975-10-03 1984-05-15 田辺製薬株式会社 キナゾリン誘導体の製法
JPS5920670B2 (ja) * 1976-04-10 1984-05-15 田辺製薬株式会社 キナゾリノン誘導体の製法
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
JP3488890B2 (ja) * 1993-11-09 2004-01-19 アグロカネショウ株式会社 ３−ｎ−置換キナゾリノン誘導体、その製造法および該化合物を含有する除草剤
PT783501E (pt) * 1995-08-02 2001-04-30 Uriach & Cia Sa J Derivados de pirimidona com actividade antifungica
KR20010083092A (ko) * 1998-07-06 2001-08-31 스티븐 비. 데이비스 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드
US6638937B2 (en) * 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
US6562830B1 (en) * 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6894057B2 (en) * 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
WO2003106435A1 (en) * 2002-06-18 2003-12-24 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
JP2006193426A (ja) * 2003-09-05 2006-07-27 Sankyo Co Ltd 置換された縮環ピリミジン−４（３ｈ）−オン化合物
US20070270589A1 (en) * 2003-11-28 2007-11-22 Mitsubishi Pharma Corporation Quinazoline Derivative and Process for Producing the Same
WO2006101521A2 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2650011A1 (en) * 2004-12-24 2013-10-16 Spinifex Pharmaceuticals Pty Ltd Method of treatment or prophylaxis
WO2008043087A2 (en) * 2006-10-05 2008-04-10 Cv Therapeutics, Inc. Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors
MX2009008099A (es) * 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
JP2010523653A (ja) * 2007-04-09 2010-07-15 ギリアード・パロ・アルト・インコーポレイテッド ステアロイルＣｏＡデサチュラーゼのインヒビターとして使用するためのプテリジノン誘導体

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110903253A (zh) * 2019-12-13 2020-03-24 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN110903253B (zh) * 2019-12-13 2020-12-25 西安交通大学医学院第一附属医院 一种喹唑啉酮类化合物及其制备方法和应用
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物

Also Published As

Publication number Publication date
CA2683925A1 (en) 2008-10-23
AU2008239689A1 (en) 2008-10-23
IL201117A0 (en) 2010-05-17
WO2008127615A1 (en) 2008-10-23
KR20100016421A (ko) 2010-02-12
RU2009141596A (ru) 2011-05-20
US20080255161A1 (en) 2008-10-16
EP2155695A1 (en) 2010-02-24
BRPI0809551A2 (pt) 2014-09-16
JP2010523674A (ja) 2010-07-15
MX2009010894A (es) 2009-10-26

Similar Documents

Publication Publication Date Title
CN101652353A (zh) 用作硬脂酰CoA去饱和酶抑制剂的3-氢喹唑啉-4-酮衍生物
US7662819B2 (en) Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors
CA2740389A1 (en) 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors
US8148376B2 (en) 3, 4-dihydroquinoxalin-2(1H)-ones for use as stearoyl CoA desaturase inhibitors
US20090105283A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
US7893066B2 (en) Pyridol[2,3-B]pyrazinones for use as stearoyl CoA desaturase inhibitors
RU2694252C2 (ru) Производные 4-(замещенного фениламино)хиназолина или их фармацевтически приемлемые соли, способ ингибирования рецепторной тирозинкиназы и фармацевтическая композиция
CN102796103A (zh) 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用
CA2924206A1 (en) Pyrimidine fgfr4 inhibitors
WO2017023986A1 (en) 3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
US20180228780A1 (en) 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
MX2014014658A (es) Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos.
CN1141298A (zh) 杂环稠合嘧啶衍生物
JP2005502662A (ja) ホスホジエステラーゼ阻害剤としての１−アルキルまたは１−シクロアルキルトリアゾロ［４，３−ａ］キナゾリン−５−オン類
CN101952257A (zh) 苯并咪唑化合物
KR20100132999A (ko) 스테아로일 ＣｏＡ 불포화 효소 억제제로서 사용하기 위한 트리아졸로피리디논 유도체
US20100267752A1 (en) 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
CN118063489A (zh) 吴茱萸碱类化合物及其制药用途
JP2011516546A (ja) ステアロイル−ＣｏＡデサチュラーゼのインヒビターとして使用するための二環式窒素含有複素環化合物
WO2019233366A1 (zh) 选择性a 2a受体拮抗剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: GILEAD PALO ALTO CO., LTD.

Free format text: FORMER OWNER: CV PHARMACEUTICAL CO., LTD.

Effective date: 20100519

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20100519

Address after: American California

Applicant after: Cv Therapeutics Inc.

Address before: American California

Applicant before: CV Therapeutics Inc.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20100217